Analgesics in France

October 2026

Analgesics in France enters 2026 with a sharp slowdown in value growth to 2%, aligning with the more mature performance seen across Western Europe, as demand remains subdued by a milder cold and flu season and reduced supply risks. While systemic analgesics continues to account for the vast majority of value, competition intensifies between leading brands and generics, resulting in sustained downward pressure on prices, especially for adult acetaminophen. Strict regulatory controls and a pharmacy-dominated retail structure constrain both product and channel innovation, but the market remained fundamentally resilient, supported by robust domestic and European production and a steady increase in consumer expenditure. Ongoing disputes between pharmacies and mass retailers over access to key products, the acceleration of e-commerce sales, and the shift toward higher-dose formulations and topical pain relief are reshaping consumer expectations and channel dynamics. For success in France, brands must navigate regulatory complexity, reinforce supply security, invest in value-added differentiation, and adapt to evolving purchasing behaviours driven by digitalisation and shifting preferences for self-medication.

USD 1,195
Request More Information

Delivery:

Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).

This report comes in PDF with additional info in Excel included.

Overview:

Understand the latest market trends and future growth opportunities for the Analgesics industry in France with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.

Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.

If you're in the Analgesics industry in France, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.

The Analgesics in France report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volume and value sizes, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent research methodology, conducted in-country

This report answers:

  • What is the market size of Analgesics in France?
  • Which are the leading brands in Analgesics in France?
  • How are products distributed in Analgesics in France?
  • How has the regulatory and operating environment for Analgesics changed in France?
  • How are considerations such as stress, self-medication and shifting consumer lifestyles shaping demand for Analgesics
  • How significant are wider health concerns and consumer awareness in determining sales?
  • Where is future growth expected to be most dynamic?

Key Data Insights

Key Industry Trends

Milder flu season and price competition slow analgesics growth as supply pressures ease
Regulatory tightening cements paracetamol and ibuprofen as the mainstays of systemic analgesics
Topical analgesics outpace systemic rivals as weather fuel demand despite price pressure
Chart 1 Value Sales 2021-2031
Chart 2 Value Sales by Category 2026
E.Leclerc to challenge pharmacy dominance as regulatory battles reshape access
Self-medication and high-dose formats set to drive systemic analgesics leadership
Chart 1 Forecast Value Sales 2021-2031
Chart 2 Forecast Value Sales by Category 2026-2031
Doliprane leads as Opella adapts its flagship brand and ibuprofen rivals lose ground
Sanofi's Doliprane sale reshapes ownership as generics press established analgesics brands
Chart 1 Company Shares 2026
Chart 2 Brand Shares 2026
Pharmacies maintains control as legislation blocks new entrants
Online pharmacies and pure players accelerate e-commerce growth
Chart 1 Retail Channels 2021-2026
Biogaran's sale to BC Partners and state intervention reshape supply sovereignty for pain relief
Bayer's Actron and Sanofi's Doliprane use reformulation to differentiate within regulatory limits
Generics, E.Leclerc's provocative campaign and online pure players intensify price competition
Chart 1 Real GDP Growth 2021-2031
Chart 2 Inflation 2021-2031
Chart 1 Population 2021-2031
Chart 2 Population by Generation 2026
Chart 3 Consumer Expenditure 2021-2031

Country Reports Disclaimer

The following categories and subcategories are included:

Analgesics

      • Adult Acetaminophen
      • Adult Aspirin
      • Adult Combination Products - Analgesics
      • Adult Diclofenac
      • Adult Dipyrone
      • Adult Ibuprofen
      • Adult Ketoprofen
      • Adult Naproxen
      • Adult OTC Triptans
      • Paediatric Acetaminophen
      • Paediatric Aspirin
      • Paediatric Combination Products - Analgesics
      • Paediatric Dipyrone
      • Paediatric Ibuprofen
      • Paediatric Naproxen
      • Acetaminophen
      • Aspirin
      • Combination Products - Analgesics
      • Diclofenac
      • Dipyrone
      • Ibuprofen
      • Ketoprofen
      • Naproxen
      • OTC Triptans
  • Topical Analgesics/Anaesthetic

Analgesics

Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).

See all of our definitions
Share:

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This report originates from Passport, our Analgesics research and analysis database.

NEW REPORT GUARANTEE

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!